Roland Fries
Research Subjects
Research Interests
Roland Fries has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Michael Böhm
Universitätsklinikum des Saarlandes
2 shared publicationsBruno Scheller
Universitätsklinikum des Saarlandes
1 shared publicationChristian Mewis
Universitätsklinikum des Saarlandes
1 shared publicationChristoph Schmitz
1 shared publicationDiana Aicher
1 shared publicationHans-Joachim Schäfers
1 shared publication
Latest Publications
- 1 August 2007
- Published by Springer Nature in Medizinische Klinik
- Vol. 102 (8) , 647-658
Aktuelle Kardiologie 2006/2007
- 1 August 2007
- Published by Springer Nature in Medizinische Klinik
- Vol. 102 (8) , 647-658
Aktuelle Kardiologie 2006/2007
- 1 July 2006
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 132 (1) , 32-37
In vitro comparison of aortic valve movement after valve-preserving aortic replacement
- 1 July 2006
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 132 (1) , 32-37
In vitro comparison of aortic valve movement after valve-preserving aortic replacement
- 13 April 2006
- Vol. 148 (15) , 62-3
[Lower leg edema. Persistent fluid accumulations have always to be clarified!].
- 13 April 2006
- Vol. 148 (15) , 62-3
[Lower leg edema. Persistent fluid accumulations have always to be clarified!].
- 8 November 2005
- Published by Wolters Kluwer Health in Circulation
- Vol. 112 (19) , 2980-2985
Sildenafil in the Treatment of Raynaud’s Phenomenon Resistant to Vasodilatory Therapy
Background— Vasodilatory therapy of Raynaud’s phenomenon represents a difficult clinical problem because treatment often remains inefficient and may be not tolerated because of side effects. Methods and Results— To investigate the effects of sildenafil on symptoms and capillary perfusion in patients with Raynaud’s phenomenon, we performed a double-blinded, placebo-controlled, fixed-dose, crossover study in 16 patients with symptomatic secondary Raynaud’s phenomenon resistant to vasodilatory therapy. Patients were treated with 50 mg sildenafil or placebo twice daily for 4 weeks. Symptoms were assessed by diary cards including a 10-point Raynaud’s Condition Score. Capillary flow velocity was measured in digital nailfold capillaries by means of a laser Doppler anemometer. While taking sildenafil, the mean frequency of Raynaud attacks was significantly lower (35±14 versus 52±18, P =0.0064), the cumulative attack duration was significantly shorter (581±133 versus 1046±245 minutes, P =0.0038), and the mean Raynaud’s Condition Score was significantly lower (2.2±0.4 versus 3.0±0.5, P =0.0386). Capillary blood flow velocity increased in each individual patient, and the mean capillary flow velocity of all patients more than quadrupled after treatment with sildenafil (0.53±0.09 versus 0.13±0.02 mm/s, P =0.0004). Two patients reported side effects leading to discontinuation of the study drug. Conclusions— Sildenafil is an effective and well-tolerated treatment in patients with Raynaud’s phenomenon.
- 8 November 2005
- Published by Wolters Kluwer Health in Circulation
- Vol. 112 (19) , 2980-2985
Sildenafil in the Treatment of Raynaud’s Phenomenon Resistant to Vasodilatory Therapy
Background— Vasodilatory therapy of Raynaud’s phenomenon represents a difficult clinical problem because treatment often remains inefficient and may be not tolerated because of side effects. Methods and Results— To investigate the effects of sildenafil on symptoms and capillary perfusion in patients with Raynaud’s phenomenon, we performed a double-blinded, placebo-controlled, fixed-dose, crossover study in 16 patients with symptomatic secondary Raynaud’s phenomenon resistant to vasodilatory therapy. Patients were treated with 50 mg sildenafil or placebo twice daily for 4 weeks. Symptoms were assessed by diary cards including a 10-point Raynaud’s Condition Score. Capillary flow velocity was measured in digital nailfold capillaries by means of a laser Doppler anemometer. While taking sildenafil, the mean frequency of Raynaud attacks was significantly lower (35±14 versus 52±18, P =0.0064), the cumulative attack duration was significantly shorter (581±133 versus 1046±245 minutes, P =0.0038), and the mean Raynaud’s Condition Score was significantly lower (2.2±0.4 versus 3.0±0.5, P =0.0386). Capillary blood flow velocity increased in each individual patient, and the mean capillary flow velocity of all patients more than quadrupled after treatment with sildenafil (0.53±0.09 versus 0.13±0.02 mm/s, P =0.0004). Two patients reported side effects leading to discontinuation of the study drug. Conclusions— Sildenafil is an effective and well-tolerated treatment in patients with Raynaud’s phenomenon.
- 15 April 2004
- Vol. 146 (16) , 39-41
[Differential diagnosis of leg edema].
Both generalized and localized edema needs to be submitted to a differential diagnostic investigation. In the case of edema affecting the lower extremities, in particular the Stemmer sign which is the inability to tent the skin at the dorsum of the toes is a useful distinguishing aid. If there is acute unilateral swelling of a leg, other processes with diffuse space-consuming processes need to be distinguished from deep venous thrombosis and secondary lymphedema. Chronic bilateral leg edema is usually due to a venous flowoff obstruction (stasis edema). Less commonly, lipedema or a primary lymphedema may be responsible for the swelling.
- 15 April 2004
- Vol. 146 (16) , 39-41
[Differential diagnosis of leg edema].
Both generalized and localized edema needs to be submitted to a differential diagnostic investigation. In the case of edema affecting the lower extremities, in particular the Stemmer sign which is the inability to tent the skin at the dorsum of the toes is a useful distinguishing aid. If there is acute unilateral swelling of a leg, other processes with diffuse space-consuming processes need to be distinguished from deep venous thrombosis and secondary lymphedema. Chronic bilateral leg edema is usually due to a venous flowoff obstruction (stasis edema). Less commonly, lipedema or a primary lymphedema may be responsible for the swelling.